Breast Cancer
Conditions
Keywords
immune response, blood samples
Brief summary
This study aims to constitute a most complete biological collection for patients treated for localized or metastatic breast cancer (in different cohorts depending on the type of systemic treatment received), in order to describe the basal immune response of patients treated for a breast cancer according to the stage of the disease, but above all to study how the different systemic treatments used in the management of breast cancer modulate this immune response.
Detailed description
The main objective of this study is to describe, depending on the type of systemic treatment received, the blood immune response before treatment and its evolution under treatment.
Interventions
OTHERblood sample
•Blood sample: * 1 heparinized tube (4 mL) for collection of plasma and storage * 1 heparinized tube (4 mL) for immunophenotyping, * 4 EDTA tubes (4 x 10 mL) for collecting white blood cells (PBMC) for cryopreservation.
Sponsors
Centre Georges Francois Leclerc
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 85 Years
Healthy volunteers
No
Inclusion criteria
1. Woman aged between 18 and 85. 2. Patient with histologically proven infiltrating breast cancer. 3. Triple negative breast cancer or RH + / HER2- (OR and RP \<10% and HER2 negative (0 or 1+ in IHC or 2+ in IHC and FISH negative) 4. Patient receiving treatment corresponding to one of these cohorts: * In a metastatic situation with establishment of treatment with Paclitaxel regardless of the treatment line * In a metastatic situation with establishment of treatment with Epirubicin - cyclophosphamide (EC) regardless of the treatment line * In a metastatic situation with establishment of treatment with Eribulin regardless of the line of treatment * In a 1st line metastatic situation with initiation of treatment with Palbociclib or Abemaciclib, or Ribociclib in combination with hormone therapy (aromatase inhibitor) 5. Patient who signed the informed consent for the study. 6. Patient fit and able to adhere to protocol for the duration of the study, including visits, scheduled specimens and follow-up. 7. Patient affiliated to the social security system.
Exclusion criteria
1. Patient unable to understand, read and / or sign informed consent. 2. Presence of cerebral or meningeal metastasis 3. Current or previous use of an immunosuppressive drug in the 14 days preceding inclusion (except intranasal corticosteroids, systemic corticosteroids at physiological doses not exceeding 10 mg per day of prednisone or its equivalent, corticosteroids for antiemetic purposes, corticosteroids used as premedication for hypersensitivity reactions (injected CT scan, taxanes, etc.) 4. Patient participating in another research that may modify the systemic treatment administered in the framework of the cohort in which she will be included. 5. Pregnant or breastfeeding woman. 6. HIV and / or HBV and / or HCV serology positive. 7. Life expectancy estimated at less than 3 months. 8. Patient's refusal. 9. Person benefiting from a protection system for adults (including tutorship and curatorship). 10. Inability to undergo medical monitoring of the trial for geographical, social or psychological reasons.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| blood immune response blood immune response blood immune response | 24 months | realization of a plasma library, immunophenotyping and a PBMC bank realization of a plasma library, immunophenotyping and a PBMC bank realization of a plasma library, immunophenotyping and a PBMC bank realization of a plasma library, immunophenotyping and a PBMC bank realization of a plasma library, immunophenotyping and a PBMC bank |
Countries
France
Contacts
Primary ContactSylvain LADOIRE, PU-PH
Backup ContactEmilie REDERSTORFF
Outcome results
None listed